###### Strengths and limitations of this study

-   We used a nested case-control design to analyse the association between perioperative urinary thromboxane metabolite (TXA-M) and major adverse cardiac and cerebrovascular events (MACCE) in a coronary artery bypass graft (CABG) cohort. This CABG cohort was from a randomised controlled trial (STICS), so the cases (56 patients with MACCE) and the 168 controls from the same cohort had the comparable baseline characteristics, which made our results more reliable and powerful.

-   We tested the TXA-M levels at different time points before and after surgery establishing more reliable association between the TXA-M levels and adverse events after surgery.

-   We have not tested TXA-M levels at later time points beyond the first day after CABG, thus, whether the TXA-M level in this study is a temporary or stable change should be verified in further studies.

Introduction {#s1}
============

Coronary artery disease (CAD) is the leading cause of mortality worldwide. As one of the commonly used revascularisation strategies, coronary artery bypass graft (CABG) surgery is the standard of care for patients with CAD with diabetes or multivessel CAD.[@R1] In the first year after CABG, thrombotic dysfunction, for example, thrombus occlusion of saphenous vein grafts (SVG),[@R2] is one of the main reasons increasing the risk of adverse events, including death, myocardial infarction (MI) and repeat revascularisation.[@R3]

Thromboxane A~2~ (TXA~2~) is an unstable metabolite of arachidonic acid (AA). Numerous studies have revealed TXA~2~ as a culprit of cardiovascular diseases.[@R5] As a platelet agonist, TXA~2~ activates adjacent platelets, provokes more platelet-dependent TXA~2~ generation, and thus triggers platelet aggregation.[@R8] Under normal conditions, TXA~2~ is dominantly synthesised by platelet via cyclo-oxygenase-1 pathway in humans. Aspirin, inhibiting platelet cyclo-oxygenase-1, has been commonly used as an antiplatelet therapy to reduce TXA~2~ generation and prevent secondary vascular thrombotic events. While, under the condition of acute inflammatory stimuli, such as surgery or cardiopulmonary bypass, the expression level of cyclo-oxygenase-2 can increase dramatically and promote the synthesis of TXA~2~, the CABG procedure enhances inflammatory process and platelet turnover, which causes the elevation of TXA~2~ by the induction of cyclo-oxygenase-2.[@R9] Previous studies have reported that TXA~2~ generation was an independent risk factor for early SVG thrombosis after CABG.[@R4]

However, whether perioperative TXA~2~ generation is associated with adverse events after CABG is unclear. We hypothesise that enhanced perioperative TXA~2~ generation is correlated with poor prognosis after CABG. We studied a cohort of 1670 patients with CABG from the Statin Therapy in Cardiac Surgery (STICS) trial (ClinicalTrials.gov number, NCT01573143)[@R10] with a nested case-control analysis, to determine whether perioperative TXA~2~ generation, measured by urinary thromboxane metabolites (TXA-M), is correlative with major adverse cardiac and cerebrovascular events (MACCE), including all-cause death, non-fatal MI, non-fatal stroke and repeat revascularisation after CABG.

Methods {#s2}
=======

Study design {#s2a}
------------

We have complied with the World Medical Association Declaration of Helsinki regarding ethical conduct of research involving human subjects and/or animals. All patients provided written informed consent to be involved in the study.

Patient enrolment {#s2b}
-----------------

Patients were selected from the STICS trial.[@R10] Between September 2011 and October 2013, 1922 patients at Fuwai hospital were randomised, among which 1670 underwent CABG ([supplementary methods](#SP1){ref-type="supplementary-material"}. For all patients, the medication of ASA stopped at least 5 days before CABG and postoperatively, starting within the first 24 hours postoperation (100 mg). All patients were required to come back for a routine outpatient follow-up visit at 1 month, 6 months and each year after discharge. The medical records of those who reported any adverse events after discharge were reviewed for further confirmation. The primary end point of follow-up was a composite of MACCE (ie, non-fatal stroke, non-fatal MI, repeat revascularisation or death from any cause)[@R11] ([supplementary methods](#SP1){ref-type="supplementary-material"}). Among the 1670 patients undergoing CABG, 15 (0.9%) were lost during the first year follow-up, and 56 out of 1655 followed-up patients (3.4%) had MACCE. With the use of a nested case-control analysis, we matched each patient with MACCE with three controls from the cohort; matching was based on sex, age, body mass index, hypertension, diabetes mellitus, smoking status, ejection fraction, COPD, previous MI, previous stroke, chronic kidney disease and peripheral vascular disease. Medication use after discharge was recorded at 1 year follow-up; for patients who missed this information we used prescription at discharge instead.
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Sample collection and preparation {#s2c}
---------------------------------

For every patient enrolled in this study, urinary samples were collected with cryogenic vials at three time spots: 1 hour before CABG (pre-CABG), 6 hours after CABG (post-CABG 6 hour) and twenty-four hours after CABG (post-CABG 24 hours). All urinary samples were stored at −80°C. Before testing, samples were thawed at 4°C for an hour and then centrifuged at 1000 g for 15 min. Finally, 100 ul from the supernatant was collected for further analysis.

Patient and public involvement {#s2d}
------------------------------

All data in this study were from the STICS trial (NCT01573143), so the present study did not involve participants and/or public in the study design and we obtained no more information or biological samples from patients in this study. Results will be disseminated to study participants via this publication.

Measurement of TXA~2~ generation {#s2e}
--------------------------------

As TXA~2~ is an unstable metabolite, we measured urinary TXA-M, including 11-dehydro-thromboxane (TXB~2)~ and 11-dehydro-2, 3-dinor TXB~2~ using the AspirinWorks 11-dehydro-TXB~2~ ELISA (Corgenix, Broomfield, Colorado, USA) and expressed as a ratio to urinary creatine as previously described.[@R13] The measurement was performed during December 2014--Janurary 2015.

Statistical analysis {#s2f}
--------------------

For demographic description of patients, we calculated the means (±SD) for continuous variables in both the MACCE and the control groups and compared them using Student's t-test; differences in discontinuous variables were evaluated using χ^2^ test. For TXA-M level, we used the median and IQR. Comparison of TXA-M levels between the two groups was conducted by Mann-Whitney analysis because its distribution was non-normally distributed. For survival analysis, pre-CABG, post-CABG 6 hours and post-CABG 24 hours urinary TXA-M were divided into tertiles according to their quantitative levels, respectively. The correlation between MACCE and TXA-M levels were estimated using the Kaplan-Meier method and log-rank test. Univariate and multivariate Cox proportional hazards regression models were used to estimate HRs and 95% CIs. Moreover, we adjusted the model by multiple variables listed in online [supplementary table S1](#SP1){ref-type="supplementary-material"}, all of which were reported to correlate with the pathogenesis and prognosis of CAD significantly and C-statistic calculations were used for logistic regression. All statistical analyses were done with SPSS V.19.0 for Windows (SPSS, Chicago, Illinois, USA).

Results {#s3}
=======

Study population characteristics {#s3a}
--------------------------------

The STICS trial includes 1670 patients undergoing CABG. During the first year of follow-up after CABG, 15 of them were lost. Among the remaining 1655 patients (99.1%), 56 had MACCE (3.4%) ([figure 1](#F1){ref-type="fig"}). For every patient with MACCE, we matched three controls without MACCE for further analysis. The baseline of the MACCE and the control groups has been presented in [table 1](#T1){ref-type="table"}. The average age of patients with MACCE was 61.7 years, and 44 out of 56 patients with MACCE (78.6%) were male. There were no differences in age, sex, body mass index, hypertension, diabetes mellitus, smoking status, COPD, peripheral vascular diseases, previous MI, chronic kidney diseases and ejection fraction between the MACCE and the control groups. In this nested case-control study, 26 (46.4%) patients in the MACCE group and 84 (50.0%) in the non-MACCE group were treated by perioperative rosuvastatin according to the study protocol of the STICS trial. After discharge, all the secondary preventive medications including aspirin, β-blockers, statins, ACE inhibitors and calcium channel blockers showed no differences between patients with MACCE and controls.

###### 

Baseline characteristics of study participants

                                             All patients (n=224)   MACCE         P values      
  ------------------------------------------ ---------------------- ------------- ------------- -------
  Age                                                                                           
   Mean - years                              61.7 (±7.9)            61.7 (±7.8)   61.7 (±8.2)   0.981
   Distribution - no. (%)                                                                       
   ≤60 years                                 100 (44.6)             75 (44.6)     25 (44.6)     1
   \>60 years                                124 (55.4)             93 (55.4)     31 (55.4)     1
  Male sex - no. (%)                         180 (80.4)             136 (81.0)    44 (78.6)     0.698
  Body mass index (kg/m^2^)                  25.9 (±2.9)            25.9 (±2.8)   25.9 (±3.2)   0.970
  Current smoking - no. (%)                  133 (59.4)             103 (61.3)    30 (53.6)     0.307
  Medical history - no. (%)                                                                     
   Hypertension                              159 (71.0)             121 (72.0)    38 (67.9)     0.552
   Diabetes mellitus                         83 (37.1)              59 (35.1)     24 (42.9)     0.299
   Chronic obstructive pulmonary disease     2 (0.9)                1 (0.6)       1 (1.8)       0.412
   Peripheral vascular disease               7 (3.1)                5 (3.0)       2 (3.6)       0.825
   Prior MI                                  76 (33.9)              55 (32.7)     21 (37.5)     0.515
   Chronic kidney disease                    3 (1.3)                3 (1.8)       0 (0.0)       0.314
  Ejection fraction (%)                      60.5 (±7.6)            60.5 (±7.6)   60.4 (±7.9)   0.923
  Rosuvastatin use in the STICS trial        110 (49.1%)            84 (50.0%)    26 (46.4%)    0.643
  Medication use after discharge - no. (%)                                                      
   Aspirin                                   217 (96.9)             163 (97.0)    54 (96.4)     0.825
   β-blocker                                 163 (72.8)             124 (73.8)    39 (69.6)     0.544
   Statins                                   158 (70.5)             120 (71.4)    38 (67.9)     0.612
   ACEI                                      52 (23.2)              40 (23.8)     12 (21.4)     0.715
   Calcium channel blocker                   52 (23.2)              36 (21.4)     16 (28.6)     0.273
  Scheduled surgery - no. (%)                                                                   
   On-pump procedure                         101 (45.1)             72 (42.9)     29 (51.8)     0.245
   Off-pump procedure                        123 (54.9)             96 (57.1)     27 (48.2)     0.245

Values are mean (±SD) or n (%).

ACEI, ACE inhibitors; MACCE, major adverse cardiac and cerebrovascular events; MI, myocardial infarction; STICS, Statin Therapy in Cardiac Surgery.

![Flow chart of study design. We recruited 1670 patients with CABG from the STICS trial. After 1 year follow-up, 56 patients had MACCE. With the use of a nested case-control analysis, we matched each patient with MACCE with three controls from the cohort; thus, a cohort of 224 patients was established for further study. CABG, coronary artery bypass graft; MACCE, major adverse cardiac and cerebrovascular events; STICS, Statin Therapy in Cardiac Surgery.](bmjopen-2017-021219f01){#F1}

Perioperative TXA-M generation between the MACCE and the control groups {#s3b}
-----------------------------------------------------------------------

To determine whether the perioperative TXA-M generation was associated with 1 year MACCE after CABG, we tested pre-CABG, post-CABG 6 hours and post-CABG 24 hours urinary TXA-M levels. In both, the MACCE and the control groups, the generation of TXA-M was elevated after CABG. Urinary TXA-M generation before CABG was 5076 pg/mg creatine in the control group, which was slightly higher than that in the MACCE group (4540 pg/mg creatine, P=0.047). The levels of TXA-M post-CABG 6 hours in patients with MACCE and controls showed no significant difference (24 016 vs 25 681 pg/mg creatine, P=0.727). However, TXA-M post-CABG 24 hours of patients with MACCE was significantly higher than that of patients without MACCE (11 101 vs 8849 pg/mg creatine, P=0.007) ([table 2](#T2){ref-type="table"}).

###### 

Urinary thromboxane metabolite (TXA-M) concentrations pre-CABG, post-CABG 6 hours and post-CABG 24 hours in patients with or without MACCE

                       MACCE   Non-MACCE   P values                                       
  -------------------- ------- ----------- --------------- ----- -------- --------------- -------
  Pre-CABG             56      4540        2383\~6524      168   5076     3398\~7593      0.047
  Post-CABG 6 hours    56      24 016      15541\~35 965   168   25 681   17612\~35 005   0.727
  Post-CABG 24 hours   56      11 101      7327\~14 624    168   8849     5530\~12 552    0.007

CABG, coronary artery bypass graft; MACCE, major adverse cardiac and cerebrovascular events.

Furthermore, we compared perioperative TXA-M generation in patients who died, patients with stroke, patients with MI and patients with repeat revascularisation with perioperative TXA-M generation in controls. Pre-CABG and post-CABG 6-hours urinary TXA-M generation showed no differences between patients who died, patients with stroke, patients with MI, patients with repeat revascularisation and controls. Post-CABG 24 hours TXA-M after CABG was significantly higher in patients who died (11 993 vs 8849 pg/mg creatine, P=0.039) and patients with stroke (11 138 vs 8849 pg/mg creatine, P=0.016). In addition, no differences were detected between patients with repeat revascularisation and controls in post-CABG 24 hours generation of TXA-M ([table 3](#T3){ref-type="table"}).

###### 

Urinary thromboxane metabolite (TXA-M) concentrations of pre-CABG, post-CABG 6 hours and post-CABG 24 hours in control patients and patients who died, patients with stroke, patients with MI and patients with repeat revascularisation

  ------------------------------------------------------------------------------------------------------------------------------------
                        Number   Pre-CABG            P values   Post-CABG 6 hours        P values   Post-CABG 24 hours      P values
  --------------------- -------- ------------------- ---------- ------------------------ ---------- ----------------------- ----------
  Patients with MACCE                                                                                                       

   Control patients     168      5076 (3398\~7593)   --         25 681 (17612\~35 005)   --         8849 (5530\~12 552)     --

   Death                16       4879 (1680\~9325)   0.596      26 689 (20423\~26689)    0.441      11 993 (8614\~23 384)   0.039

   Stroke               26       4583 (2713\~5875)   0.197      26 156 (13426\~36 372)   0.847      11 138 (8764\~15 021)   0.016

   MI                   2        2550\               0.075      17 029\                  0.225      13 585\                 0.444
                                 (−)                            (−)                                 (−)                     

   Revascularisation    12       3384 (2554\~6765)   0.931      21 502 (12965\~32 440)   0.335      8059 (6577\~13 642)     0.931
  ------------------------------------------------------------------------------------------------------------------------------------

Values are median (IQR).

CABG, coronary artery bypass graft; MI, myocardial infarction; MACCE, major adverse cardiac and cerebrovascular events.

Survival analysis of perioperative TXA-M levels and MACCE {#s3c}
---------------------------------------------------------

Next, we performed survival analysis of perioperative TXA-M levels and MACCE. We divided pre-CABG (tertile 1:\~3750; tertile 2: 3750\~6150; tertile 3: 6150\~, pg/mg creatine), post-CABG 6 hours (tertile 1:\~19 750; tertile 2: 19750\~30 300; tertile 3: 30300\~, pg/mg creatine) and post-CABG 24 hours (tertile 1:\~7000; tertile 2: 7000\~12 000; tertile 3: 12000\~, pg/mg creatine) urinary TXA-M into tertiles according to their quantitative levels.

There were no significant differences of MACCE risk regarding to tertiles of pre-CABG (P~trend~=0.075) and post-CABG 6 hours urinary TXA-M (P~trend~=0.755). However, post-CABG 24 hours TXA-M was significantly associated with 1 year MACCE (P~trend~=0.022). Patients whose post-CABG 24 hours TXA-M was in the intermediate tertile had an elevated HR of 2.22 in comparison to patients generating lower level of post-CABG 24 hours TXA-M (95% CI 1.04 to 4.71, P=0.038), and the higher tertiles of post-CABG 24 hours TXA-M bear an even higher HR of 2.81 (95% CI 1.35 to 5.85, P=0.006). Further, we adjusted the model by multiple variables listed in online [supplementary table S1](#SP1){ref-type="supplementary-material"}. After adjusting, post-CABG 24 hours generation of TXA-M still exhibited significant association with MACCE (P~trend~=0.018). MACCE risk of patients who generated intermediate level of post-CABG 24 hours urinary TXA-M was 2.67 (95% CI 1.20 to 5.90, P=0.016) times higher than those who generated low level of post-CABG 24 hours TXA-M, and high tertile of TXA-M generation resulted in a risk 2.86 (95% CI 1.34 to 6.13, P=0.007) times more than the low tertile ([table 4](#T4){ref-type="table"}, [figure 2](#F2){ref-type="fig"}).

###### 

Cox regression analysis of MACCE according to levels of pre-CABG, post-CABG 6 hours and post-CABG 24 hours urinary thromboxane metabolite (TXA-M)

                       Tertile   Unadjusted   Adjusted\*                                
  -------------------- --------- ------------ ------------ ------- ------------ ------- -------
  Pre-CABG             1         --           --           0.075   --           --      0.066
  2                    0.54      0.28\~1.01   0.055        0.52    0.27\~1.03   0.062   
  3                    0.55      0.29\~1.03   0.062        0.48    0.25\~0.95   0.036   
  Post-CABG 6 hours    1         --           --           0.755   --           --      0.564
  2                    1.21      0.64\~2.27   0.556        1.33    0.68\~2.22   0.404   
  3                    0.92      0.50\~1.88   0.923        0.94    0.46\~1.93   0.862   
  Post-CABG 24 hours   1         --           --           0.022   --           --      0.018
  2                    2.22      1.04\~4.71   0.038        2.67    1.20\~5.90   0.016   
  3                    2.81      1.35\~5.85   0.006        2.86    1.34\~6.13   0.007   

Adjusted by all the variables listed in online [supplementary table S1](#SP1){ref-type="supplementary-material"} (age, sex, body mass index, current smoking, hypertension, diabetes mellitus, chronic obstructive pulmonary disease, peripheral vascular disease, prior myocardial infarction, chronic kidney disease, ejection fraction, on-pump procedure, aspirin, β-blocker, statins, ACE inhibitors, calcium channel blocker).

CABG, coronary artery bypass graft; MACCE, major adverse cardiac and cerebrovascular events.

![Kaplan-Meier curves of MACCE-free survival rate according to post-CABG 24 hours concentration of urinary thromboxane metabolite (TAX-M). Analysis of MACCE-free survival rate according to concentration tertiles of post-CABG 24 hours urinary TAX-M. (A) Unadjusted curve of MACCE-free survival rate; (B) Curve of MACCE-free survival rate adjusted by variables listed in online [supplementary table S1](#SP1){ref-type="supplementary-material"}. CABG, coronary artery bypass graft; MACCE, major adverse cardiac and cerebrovascular events.](bmjopen-2017-021219f02){#F2}

In addition, we calculated the C-statistics of the models. Under logistic regression, the C-statistic of clinical factors containing all variables listed in online [supplementary table S1](#SP1){ref-type="supplementary-material"} was 0.64 (95% CI 0.55 to 0.72), the C-statistic of post-CABG 24 hours TAX-M was 0.62 (95% CI 0.54 to 0.70). Combining post-CABG 24 hours TAX-M with clinical factors, the C-statistic increased to 0.68 (95% CI 0.60 to 0.76), which indicated the predictive value was improved by adding post-CABG 24 hours TAX-M (online [supplementary table S2)](#SP1){ref-type="supplementary-material"}.

Discussion {#s4}
==========

In this study, we used a nested case-control design to analyse the association between perioperative urinary TXA-M and MACCE in a CABG cohort. According to our results, post-CABG 24 hours urinary TXA-M shows significant association of 1 year MACCE. Post-CABG 24 hours TXA-M of patients with MACCE is significantly higher than that of patients without MACCE. In addition, risk stratification according to the post-CABG 24 hours urinary TXA-M level predicts 1 year MACCE after CABG. Patient whose post-CABG 24 hours urinary TXA-M is in the highest tertile bears almost three times higher risk than those in the lowest tertile. These results indicate that post-CABG 24 hours urinary TXA-M has the potential to be a risk predictor of adverse events after CABG in future clinical practice.

TXA~2~ originates from AA. The first two steps of AA metabolism are the oxidation catalysed by cyclo-oxygenase-1 or cyclo-oxygenase-2. With these two isoforms of cyclo-oxygenase, AA is synthesised into hydroperoxy endoperoxide PGG2 and its subsequent reduction to the hydroxy endoperoxide PGH2, which would be transformed by TXA synthase into TXA2.[@R14] TXA~2~ has a very short half-life and undergoes hydrolysis to the inactive TXB~2~ without enzyme, then further metabolises to TXA-M (11-dehydro-TXB~2~ and 11-dehydro-2,3-dinor TXB~2~) and is excreted in the urine. In previous studies, TXA-M has been reported to be associated with increased MI, stroke or cardiovascular death rate in patients with high cardiovascular risk.[@R15] Moreover, TXA-M also correlates with the increase of cardiovascular events and mortality in patients with atrial fibrillation.[@R16] For patients with CABG, the urinary TXA-M level is associated with SVG patency.[@R4] Our study demonstrates that perioperative TXA-M level is associated with adverse events in the first year after CABG for the first time.

In our study, pre-CABG TXA-M has a marginally significant association with 1 year MACCE after CABG; patients who generate high levels of TXA~2~ tend to have low risks of MACCE. As the P value of this association is marginal, further study should be undertaken out to confirm this correlation. Urinary TXA-M increases sharply at 6 hours after CABG, which may be caused by the turnover of newly generated platelets and increased inflammation induced by the surgical procedure. At 24 hours after CABG, urinary TXA-M decreases compared with post-CABG 6 hours urinary TXA-M, which is mainly caused by decreased inflammatory response. However, the generation of urinary TXA-M still remains at a relatively high level 24 hours after CABG compared with the normal status. The main reason for this phenomenon is the cyclo-oxygenase-2-derived thromboxane synthesis. Under normal conditions, an overwhelming majority of TXA~2~ is generated by platelet cyclo-oxygenase-1. As an isoform of cyclo-oxygenase, cyclo-oxygenase-2 is mainly activated during the inflammatory process and has been reported to play important roles in the process of atherosclerosis and the progression of CAD. In response to the inflammatory stimuli triggered by the CABG procedure,[@R17] the expression of cyclo-oxygenase-2 is augmented 10--20-fold in nucleated cells.[@R14] Besides, platelet turnover enhanced by the CABG procedure also elevates platelet cyclo-oxygenase-2 expression.[@R19] Aspirin irreversibly inhibits cyclo-oxygenase by acetylating serine 530 of cyclo-oxygenase-1 or serine 516 of cyclo-oxygenase-2,[@R21] but cyclo-oxygenase-2 is \~170-fold less sensitive to inhibition by aspirin than cyclo-oxygenase-1.[@R24] So the cyclo-oxygenase-2-derived thromboxane synthesis cannot be effectively inhibited by aspirin, which may contribute to the increased MACCE rate after CABG.

Apart from cardiac surgery, TXA-M has also been described as a potential predictive biomarker of MACCE in patients with high cardiac risk and in patients with acute MI. Eikelboom *et al* [@R15] first found that urinary concentrations of TXM predicted future risk of MI or cardiovascular death. These findings raised the possibility that elevated urinary TXM levels identify patients who are relatively resistant to aspirin and who may benefit from additional antiplatelet therapies or treatments that more effectively block in vivo thromboxane production or activity found in aspirin-treated patients. Then, Eikelboom *et al* [@R25] suggested that urinary concentrations of TXM are an externally valid and potentially modifiable determinant of stroke, MI, or cardiovascular death in patients at risk for atherothrombotic events. In patients with acute MI, Szczeklik *et al* [@R26] found that urine TXM could predict 1 year MACCE in patients with acute MI and provide prognostic information on left ventricular performance.

Although, our results indicate urinary TXA-M has the potential to be a risk predictor of adverse events after CABG, this study has several potential limitations. First, the stability of the high urinary TXA-M excretion phenotype is unknown. In other words, we have not tested TXA-M levels at later time points beyond the first day after CABG, thus, whether the TXA-M level in this study is a temporary change or a stable one should be verified in further studies. Second, as a nested case-control study, we did not test TXA-M levels for all patients in the STICS cohort, which mildly reduces the strength of our findings. So a further prospective study focused on this issue should be undertaken to validate our findings.

In summary, in a nested case-control study, we conclude that the perioperative urinary TXA-M level is associated with 1 year adverse events after CABG, which raises the potential possibility that high levels of perioperative TXA-M identify patients with high risk of post-CABG adverse events.
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